Korean J Gastroenterol.  2017 Aug;70(2):61-63. 10.4166/kjg.2017.70.2.61.

The Clinical Relevance of Tumor Marker CA 19-9

• Lee YS

• KMID: 2391362
• DOI: http://doi.org/10.4166/kjg.2017.70.2.61

Abstract

No abstract available.

MeSH Terms

CA-19-9 Antigen
Biomarkers, Tumor
Carcinoma
Prognosis
Immunohistochemistry
Antigens, Tumor-Associated, Carbohydrate
CA-19-9 Antigen
Biomarkers, Tumor
Antigens, Tumor-Associated, Carbohydrate

Reference

1. Galli C, Basso D, Plebani M. CA 19–9: handle with care. Clin Chem Lab Med. 2013; 51:1369–1383.

2. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979; 5:957–971.

3. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19–9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004; 19:182–186.

4. Del Favero G, Fabris C, Plebani M, et al. CA 19–9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer. 1986; 57:1576–1579.

5. Frebourg T, Bercoff E, Manchon N, et al. The evaluation of CA 19–9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer. 1988; 62:2287–2290.

6. Kim J, Lee YS, Hwang IK, et al. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19–9 in pancreatic ductal adenocarcinoma. J Korean Med Sci. 2015; 30:259–263.

7. Kondo N, Murakami Y, Uemura K, et al. Elevated perioperative serum CA 19–9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014; 110:422–429.

8. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007; 33:266–270.

9. Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990; 85:350–355.

10. Kim BJ, Lee KT, Moon TG, et al. How do we interpret an elevated carbohydrate antigen 19–9 level in asymptomatic subjects? Dig Liver Dis. 2009; 41:364–369.

11. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT. Elevation of CA 19–9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal. 2007; 21:193–196.

12. Parra JL, Kaplan S, Barkin JS. Elevated CA 19–9 caused by hashimoto's thyroiditis: review of the benign causes of increased CA 19–9 level. Dig Dis Sci. 2005; 50:694–695.

13. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19–9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000; 26:474–479.

14. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT. Low efficacy of serum levels of CA 19–9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology. 2006; 53:1–4.

15. Marrelli D, Caruso S, Pedrazzani C, et al. CA19–9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009; 198:333–339.

16. Barone D, Onetto M, Conio M, et al. CA 19–9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers. 1988; 3:95–100.

17. Kim MS, Jeon TJ, Park JY, et al. Clinical interpretation of elevated CA 19–9 levels in obstructive jaundice following benign and malignant pancreatobiliary disease. Korean J Gastroenterol. 2017; 70:96–102.